INTRODUCTION
============

Carcinoembryonic antigen (CEA) was first isolated from human colorectal cancer (CRC) tissue in 1965 by Gold and Freedman \[[@b1-ac-2019-11-13],[@b2-ac-2019-11-13]\]. It is a foetal glycoprotein and is not usually produced in significant quantity after birth. CEA can become elevated in a number of pathologies. The most common clinical use is surveillance for recurrence of CRC. CEA levels are also sometimes measured in patients without a history of CRC. Elevated CEA in both situations presents a management dilemma to the colorectal surgeon, particularly in deciding the appropriate tests and the subsequent follow-up if those tests are inconclusive, and this led us to conduct this review. This review aims to evaluate the role of CEA in clinical colorectal practice, including the prognostic significance of CEA in patients with CRC, the role of CEA in follow-up after CRC resection, and the management of patients with raised CEA and no history of CRC.

METHODS
=======

A systematic search was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The MeSH headings "Carcinoembryonic antigen," "CEA," and "Colorectal Neoplasm" were used to identify relevant studies in the PubMed and Cochrane Library Databases.

Studies included had to be published in English from January 1, 1990, to April 30, 2017, be full text articles, and have comparison groups in which the CEA level was used to determine a component of management or outcome. Data were extracted from the included articles by 2 authors according to the aims of our review: prognostic significance of CEA in patients with CRC, role of CEA in follow-up after CRC resection, and management of patients with raised CEA and no history of CRC. Results were described qualitatively. No statistical analyses were performed.

RESULTS
=======

Of the 2,712 papers identified, 271 were screened in abstract form by 2 authors independently. Thirty-two were deemed relevant, after which the full texts of the articles were obtained and reviewed by 2 authors ([Fig. 1](#f1-ac-2019-11-13){ref-type="fig"}). A hand search of the reference lists found no additional studies.

Preoperative CEA and prognosis
------------------------------

Most trials were retrospective ([Table 1](#t1-ac-2019-11-13){ref-type="table"}). Elevated preoperative CEA predicted overall survival across stage I to stage III CRC, with elevated preoperative CEA carrying a 62% increase in the danger of death compared with a normal CEA level \[[@b3-ac-2019-11-13]\]. The 5-year disease-free survival was 84.6% vs. 69.8% \[[@b4-ac-2019-11-13]\], and the 5-year overall survival was 74.5% vs. 63.4% \[[@b5-ac-2019-11-13]\]. However, a study of 2 cohorts with Duke C cancer, 1990--2000 and 2001--2004, found that the predictive value of preoperative CEA was lost in the more recent cohort \[[@b6-ac-2019-11-13]\], and may be due to improved chemotherapy regimens. Higher preoperative CEA levels were associated with advanced disease stage.

Postoperative CEA and prognosis
-------------------------------

Kim et al. \[[@b7-ac-2019-11-13]\] hypothesized that after curative surgery, and therefore after resection of the source of CEA, CEA levels would decrease exponentially. CEA was measured preoperatively and at day 7 and day 30 postoperatively. In the patient group where the CEA level had decreased exponentially, survival was significantly greater than it was in the group where CEA remained elevated, with a trend to increased disease-free survival. Similarly, in patients with stage 4 CRC who underwent a R0 resection, elevated postoperative CEA and CA 19-9 were associated with reduced disease-free survival \[[@b8-ac-2019-11-13]\]. Failure of the CEA to return to normal after surgery was indicative of residual or recurrent disease, with CEAs over 10 ng/mL being strongly associated with metastatic disease.

Preoperative CEA and response to neoadjuvant treatment
------------------------------------------------------

In rectal cancer, elevated pretreatment CEA levels are associated with a poor response to neoadjuvant treatment, with a retrospective analysis of patients with stage I--III rectal cancer showing significantly decreased pathological complete response, pathological tumor regression, tumor downstaging, and overall survival \[[@b9-ac-2019-11-13]\].

CEA in follow-up after CRC resection
------------------------------------

Two recent meta-analyses have shown no survival benefit with increased surveillance after resection for CRC \[[@b10-ac-2019-11-13], [@b11-ac-2019-11-13]\]. For CEA specifically, we identified 8 randomized controlled trials (RCT, [Table 2](#t2-ac-2019-11-13){ref-type="table"}). In a RCT looking at managing a rising CEA with a second-look laparotomy compared to conservative treatment \[[@b12-ac-2019-11-13]\], no survival advantage was noted, and the study was terminated. CEA began increasing 323 days prior to the onset of clinically evident recurrent disease. A subgroup analysis was not performed, so whether the R0 resection of recurrent or metastatic disease had improved disease-specific survival compared to those with unresectable disease was not clear. The results were also difficult to interpret in the modern setting, as today, a 'second look' laparotomy would only be performed on patients with proven resectable disease, and this selected group would be expected to have an improved survival if compared to patients with widespread disease.

More recent trials \[[@b13-ac-2019-11-13]-[@b21-ac-2019-11-13]\] compared a standard follow-up regimen to a higher intensity follow-up, though the regimens were heterogeneous ([Table 3](#t3-ac-2019-11-13){ref-type="table"}). In the FACs (Follow-up After Colorectal Surgery) trial \[[@b15-ac-2019-11-13]\], more intensive follow-up with CEA and computed tomography (CT) scanning increased the rate of surgical treatment for recurrent disease, but without survival advantage. The accuracy of a single CEA measurement was poor, with the conclusion that the CEA trend, rather than stand-alone measurements, should be used \[[@b22-ac-2019-11-13]\].

The Dutch trial 'CEAwatch' investigated the effect of the intensity of the CEA measurement on the detection of recurrent disease and the proportion of curable recurrences \[[@b16-ac-2019-11-13]\]. Here, an elevated CEA would trigger repeat CEA testing and, if maintained, chest/abdomen CT. Intensive surveillance (8 weekly CEA) detected more patients with recurrence who had undergone a curative treatment, defined as an R0 resection, compared to the control group (3 monthly CEA: 35% vs. 22%) \[[@b16-ac-2019-11-13]\]. No improvement in overall or disease-free survival was found. The only survival benefit was when recurrences were detected by using CEA or imaging as compared to those detected by using patients' self-reported symptoms \[[@b23-ac-2019-11-13]\]. Intensive CEA testing was also found to be cost effective \[[@b17-ac-2019-11-13]\]. The GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata) trial investigated intensive surveillance by imaging for patients with Dukes B2-C CRC \[[@b18-ac-2019-11-13]\]. In the intensive surveillance arm, recurrences were detected 5.9 months earlier, but no difference in overall survival was reported.

The threshold of serum CEA used to trigger further investigations is controversial and has been addressed by a Cochrane review including 52 studies \[[@b24-ac-2019-11-13]\]. Sensitivity and specificity were 82% and 80% for a 2.5 ng/mL cutoff, 71% and 88% for 5 ng/mL, and 68% and 97% for 10 ng/mL, respectively. The review concluded that 10 ng/mL should be used as the threshold to trigger further investigations. Furthermore, the diagnostic accuracy of the postoperative CEA level in detecting recurrence is affected by the preoperative value. With a threshold of 5 ng/mL at 6 months, in patients with curatively resected colon cancer and normal preoperative CEA, the diagnostic accuracy for recurrence was 89.1%, in contrast to patients with an elevated preoperative CEA in whom the accuracy was 58.4%; an increased threshold of \> 8 ng/mL in this latter group improved diagnostic accuracy to 75.6% \[[@b25-ac-2019-11-13]\].

The hypothesis that CEA level reflects tumor burden in patients with metastatic disease has also been studied by assessing treatment response to chemotherapy. Huang et al. \[[@b26-ac-2019-11-13]\] retrospectively analysed 447 patients with metastatic CRC who had undergone resection of the primary tumor and adjuvant chemotherapy. The ratio of posttreatment (after 6 courses of chemotherapy) to pretreatment CEA was strongly correlated with the radiological response and with overall survival \[[@b26-ac-2019-11-13]\]. Similarly, in patients with metastatic CRC receiving first-line chemotherapy, there were distinct CEA level slopes according to type of radiological response i.e., progression, partial response, and stable disease \[[@b27-ac-2019-11-13]\], suggesting that CEA levels and ratios have a role in the early assessment of treatment response in stage IV CRC. In the FIRE-3 trial, the CEA trend reflected response to targeted therapy \[[@b28-ac-2019-11-13]\] in patients with (K)RAS wild-type metastatic CRC. First-line FOLFIRI plus cetuximab gave better overall survival than FOLFIRI plus bevacizumab (28.7 months vs. 25.0 months) \[[@b29-ac-2019-11-13]\], with a corresponding faster and greater decrease in CEA level. In the cetuximab arm, CEA responders, defined as a decrease of at least 75%, had better disease-free and overall survivals than CEA nonresponders.

At the cellular level, a correlation between the immunohistochemical status of CEA staining and the serum CEA level was found in colorectal metastases, but not in the primary tumors \[[@b30-ac-2019-11-13]\], suggesting that serum CEA levels are influenced both by the production of CEA in tumor cells and by its release into the bloodstream. Positive staining for CEA in metastatic tissue also carried a worse survival. Overexpression of CEA has been reported to inhibit Natural Killer cells and cytotoxic lymphocytes, which may dampen the immune response to metastases \[[@b31-ac-2019-11-13]\].

What to do for a patient with a raised CEA and no history of CRC
----------------------------------------------------------------

Whilst no specific trials have addressed what to do for a patient with a raised CEA and no history of CRC, studies have evaluated CEA in screening and diagnosis ([Table 4](#t4-ac-2019-11-13){ref-type="table"}). In patients with elevated CEA, the chance of finding CRC is increased (4.6% vs. 1.3%) \[[@b32-ac-2019-11-13]\]. CEA is also a predictor of other diseases, including other cancers, diabetes, chronic lung disease and liver disease \[[@b33-ac-2019-11-13]\]. A combination of biomarkers, including CEA, CA 19-9, prostate-specific antigen, and CA125, increases the sensitivity of CEA as a screening modality \[[@b34-ac-2019-11-13], [@b35-ac-2019-11-13]\]. In a patient with raised CEA, a detailed history and clinical assessment are likely to be the most important first steps. No evidence was found to support CEA being used as a screening tool.

DISCUSSION
==========

The available evidence supports the use of CEA in surveillance of CRC, particularly in postoperative follow-up. However, no evidence supports its use in screening and diagnosis of CRC, as CEA may be elevated in patients with other pathologies \[[@b2-ac-2019-11-13], [@b36-ac-2019-11-13]-[@b38-ac-2019-11-13]\] and many CRC patients will have a normal CEA. Serum levels \> 3-5 ng/mL are deemed to be elevated \[[@b39-ac-2019-11-13], [@b40-ac-2019-11-13]\]. Higher baseline levels occur in males, smokers and the elderly \[[@b39-ac-2019-11-13], [@b40-ac-2019-11-13]\]. Elevated CEA levels have been associated with a number of benign and malignant conditions ([Table 5](#t5-ac-2019-11-13){ref-type="table"}). CEA is used most frequently in CRC, but it is also a tumor marker in mucinous adenocarcinomas of the endocervix and ovary, as well as in keratinising squamous cell carcinomas of the cervix \[[@b41-ac-2019-11-13]\]. CEA levels \>10 ng/mL or trending upwards are more commonly associated with malignant conditions \[[@b40-ac-2019-11-13]-[@b43-ac-2019-11-13]\]. Levels \> 20 ng/mL are suspicious for metastatic disease \[[@b42-ac-2019-11-13], [@b44-ac-2019-11-13]-[@b46-ac-2019-11-13]\]. As CEA is primarily metabolized in the liver, hepatic dysfunction and biliary obstruction can be associated with raised CEA levels.

In view of the high first-pass hepatic metabolism of CEA (≥90%), very high CEA levels tend to be due to CEA-producing tumors or metastases outside the portal venous drainage territory or to locally advanced tumors within the portal venous system's drainage territory. Tumor differentiation also affects CEA level \[[@b45-ac-2019-11-13]-[@b47-ac-2019-11-13]\], with 80% of well-differentiated CRCs producing CEA and only 60% of poorly-differentiated tumors produce it \[[@b48-ac-2019-11-13]\], making surveillance less reliable. Following CRC resection in patients with normal hepatic function, a 95% reduction to the steadstate postoperative CEA level takes five half-lives, i.e., 35 days \[[@b39-ac-2019-11-13], [@b44-ac-2019-11-13], [@b47-ac-2019-11-13]\].

CEA levels correlate with prognosis \[[@b49-ac-2019-11-13]-[@b51-ac-2019-11-13]\]. In CRC, elevated preoperative CEA level (\>5 ng/mL) is associated with a higher recurrence rate and disease-related mortality \[[@b50-ac-2019-11-13]-[@b54-ac-2019-11-13]\]. A postoperative CEA decrease is also a prognostic indicator \[[@b55-ac-2019-11-13], [@b56-ac-2019-11-13]\], predicting improved overall survival and disease-free survival \[[@b28-ac-2019-11-13]\]. This also applies to those having liver surgery for colorectal metastases \[[@b57-ac-2019-11-13]\]. CEA level has also been correlated with the presence of circulating cancer cells \[[@b54-ac-2019-11-13]\].

The role of pretreatment CEA level in predicting response to chemotherapy or radiotherapy is uncertain, with some studies showing no correlation \[[@b58-ac-2019-11-13]\] and with others showing that, compared to CEA \<3 ng/mL, an elevated pretreatment CEA (\>9 ng/mL) was associated with a poor response to long-course chemoradiotherapy \[[@b59-ac-2019-11-13]\]. Reduction of CEA following neoadjuvant chemoradiotherapy for rectal cancer has prognostic significance \[[@b60-ac-2019-11-13]\], with CEA ≤5 ng/mL being correlated with increased complete clinical and pathological response and better overall and disease-free survivals. High posttreatment CEA levels may, therefore, identify patients for adjuvant treatment and intensive surveillance, and may perhaps be a relative contraindication to 'watch and wait' in patients with apparently complete clinical response.

Surveillance recommendations for CEA in CRC patients vary. The American Society of Clinical Oncology (ASCO) recommends preoperative CEA and postoperative CEA every 3--6 months for at least 5 years \[[@b61-ac-2019-11-13], [@b62-ac-2019-11-13]\]. The UK National Institute of Clinical Excellence recommends CEA levels be measured every 6 months for at least 3 years \[[@b63-ac-2019-11-13]\]. In addition, ASCO \[[@b61-ac-2019-11-13]\] recommends CEA for monitoring the response of metastatic disease to systemic therapy. The CEA doubling time is affected by rate of growth of metastases and by site of recurrence \[[@b64-ac-2019-11-13], [@b65-ac-2019-11-13]\].

CRC surveillance: management of patients with elevated CEA levels
-----------------------------------------------------------------

A patient with an elevated or progressively rising CEA level with previous CRC should be investigated for recurrent disease ([Fig. 2](#f2-ac-2019-11-13){ref-type="fig"}), initially with cross-sectional imaging (CT scan or positron emission tomography-CT \[PET-CT\]) of the chest, abdomen and pelvis, and not colonoscopy because of CEA's first-pass metabolism. Both the British Royal Society of Radiology \[[@b66-ac-2019-11-13]\] and the US oncology guidelines \[[@b67-ac-2019-11-13]\] suggest only performing a PET-CT when other imaging has been normal. If these investigations are negative, a repeat CEA level with clinical review at 3 months is suggested. If the CEA level remains stable without clinical evidence of recurrence, continued CEA measurements every 3 months and clinical review are encouraged. If the CEA level is increasing or \>10 ng/mL or if clinical evidence of recurrence is found, repeat cross-sectional imaging is suggested.

Patients referred with *de novo* elevated CEA
---------------------------------------------

While CEA should not be used as a diagnostic tool, it often is by the overexuberant health professional. This then raises the dilemma of determining if the elevated CEA is significant, in the absence of a previous history of CRC ([Fig. 3](#f3-ac-2019-11-13){ref-type="fig"}). If the patient has a history of previous CEA-producing malignancy ([Table 5](#t5-ac-2019-11-13){ref-type="table"}), the patient should be evaluated in accordance with that particular malignancy.

In the absence of a history of a previous CEA-producing tumor, evaluation begins with a thorough history and clinical examination, looking for relevant symptoms and signs of CEA-producing benign and malignant conditions ([Table 5](#t5-ac-2019-11-13){ref-type="table"}), and smoking history. Further investigations would include repeat CEA, full blood count, and iron studies, liver and renal function tests, determinations of the CA 125 and calcitonin levels, and so on, as indicated from the clinical review.

If the clinical review does not raise any suspicion of a particular disease process and CEA is \<10 ng/mL, no further investigations are recommended at this stage. The patient should be advised to stop smoking for cardiovascular and respiratory health. Determination of the CEA level and a clinical review should be repeated at 3 months. If the level falls, determination of the CEA level and a clinical review should be repeated at 6-month intervals until the CEA level returns to normal or until 2 consecutive decreases are noted. If, however, after 3--6 intervals, the CEA level remains above 5 ng/mL or if the level exceeds 10 ng/mL at any stage, further investigations (CT scan, PET-CT or organ-specific investigations) are indicated.

If the CEA level is greater than 10 ng/mL at the time of presentation, a PET-CT or whole-body CT can be used to look for primary and/or secondary malignancy, unless clinical review indicates a likely site of malignancy to guide a more specific investigations Depending on access and local costs, using a PET-CT scan before organ-specific testing might be more cost effective. If these preliminary tests are negative, a repeat CEA should be performed 3 months later with a clinical review. The clinical review is more important at this stage. A CEA level persistently \>10 ng/mL at 1 year requires repeat investigation. Rising CEA levels \>10 ng/mL or levels \> 20 ng/mL require investigation every year until the underlying cause is detected.

In the clinical scenario of patients with de novo elevated CEA, our practice would be to investigate with whole-body PET-CT before organ-specific investigations, unless clinical evidence suggesting a specific site for the malignancy is found. If PET-CT scanning is not available, we suggest whole-body CT.

CONCLUSION
==========

Current evidence suggests CEA has a role in the prognostication and treatment planning for and the surveillance of patients with CRC. The use of algorithms will help guide how patients presenting with elevated CEA should be further elevated.
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![Algorithm 1: Investigation pathway for a patient with a raised carcinoembryonic antigen (CEA) with a previous history of a CEA-expressing cancer. ^a^Organ-specific investigations: tumor markers, CT scan, colonoscopy, gastroscopy, mammography, cystoscopy, Ultrasound Scan (US), bone scan, biopsy, other test as required. PET/CT, positron emission tomography-computed tomography.](ac-2019-11-13f2){#f2-ac-2019-11-13}

![Algorithm 2: Investigation pathway for a patient with a *de novo* raised carcinoembryonic antigen (CEA). ^a^Organ-specific investigations: tumor markers, CT scan, colonoscopy, gastroscopy, mammography, cystoscopy, US, bone scan, biopsy, other test as required. Clinical review includes: a full history and examination of the thyroid, breast, thorax, abdomen and pelvis, visual field testing, fundoscopy, long bones examination. Look for melanoma. In females, cervical examination. In males, a prostate examination. PET/CT, positron emission tomography-computed tomography.](ac-2019-11-13f3){#f3-ac-2019-11-13}

###### 

CEA and prognosis: selected studies

  Author                                     Year   Origin    Study type                                        Study summary                                                      Endpoint                                         No. of patients                                      Age (yr)^[a](#tfn1-ac-2019-11-13){ref-type="table-fn"}^            Sex ratio (%male)                        Outcome summary
  ------------------------------------------ ------ --------- ------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stelzner \[[@b68-ac-2019-11-13]\]          2005   Germany   Cohort (retrospective database)                   Database review for predictors of survival in colorectal cancer    Overall survival in stage IV colorectal cancer   186                                                  68.6 (range, 30--92)                                               54.3                                     Preop CEA ≥ 5 ng/mL associated with decreased overall survival in stage IV disease.
  Katoh \[[@b6-ac-2019-11-13]\]              2008   Japan     Cohort (retrospective database)                   Review of preop CEA levels in Dukes C patients                     Survival                                         Retrospective: 237; prospective: 197                 54.4% ≥ 60 in retrospective; 63.5% ≥ 60 in prospective             Retrospective: 59.1; prospective: 57.4   CEA ≤ 2.5 ng/mL was a predictor of disease-free survival in Dukes C in earlier cohort. Association lost in later cohort, possibly due to improved chemotherapy.
  Kim \[[@b7-ac-2019-11-13]\]                2009   Korea     Cohort (retrospective data base)                  Postoperative analysis of CEA preop and day 7 and 30-day post op   Survival                                         122                                                  57.56 ± 12.24                                                      62.3                                     Significant decrease in survival if CEA levels remain elevated in postop period.
  Sun \[[@b69-ac-2019-11-13]\]               2009   Taiwan    Cohort (retrospective data base)                  Retrospective review of potential prognostic markers               Disease-free and overall survival                1,367                                                66 (IQR, 19-25)                                                    55.4                                     Preop CEA ≥ 5 ng/mL 2.38x more likely to die of cancer than those with CEA ≤5 ng/mL (P ≤ 0.001)
  Thirunavukarasu \[[@b70-ac-2019-11-13]\]   2015   USA       Cohort (retrospective SEER database)              Review of preop CEA levels                                         5-Year overall and disease-specific mortality    16,619                                               67.4 ± 13.8                                                        49.7                                     Elevated CEA was associated with worse overall and disease-specific mortality
  Becerra \[[@b3-ac-2019-11-13]\]            2016   USA       Cohort (retrospective data base)                  Review of preop CEA levels in Stage I-III CRC                      Overall survival                                 69,512                                               Normal CEA: 69.1 ± 13.0; elevated CEA: 70.3 ± 12.9                 Normal CEA: 49.0; elevated CEA: 43.7     Preop CEA level is associated with overall survival
  Ozawa \[[@b4-ac-2019-11-13]\]              2017   Japan     Cohort (retrospective National Cancer Database)   Review of preop CEA levels                                         5-Year disease-free survival                     7,296                                                65.3 ± 11.2                                                        54.4                                     Preop CEA level is independently associated with 5-year disease-free survival
  Spindler \[[@b5-ac-2019-11-13]\]           2017   USA       Cohort (retrospective National Cancer Database)   Review of preop CEA levels in Stage II CRC                         5-Year overall survival                          74,945                                               Normal CEA: 70 (IQR, 59-79); elevated CEA 72 (IQR, 6081)           Normal CEA: 49.3 Elevated CEA: 43.4      Preop elevated CEA is associated with reduced 5-year overall survival
  Kim \[[@b71-ac-2019-11-13]\]               2017   Korea     Retrospective and prospective cohort              To determine cutoff values for preop CEA in Stage III CRC          5-Year overall and disease-free survival         Retrospective cohort: 965; prospective cohort: 268   Retrospective: 60 (range, 14-84); prospective: 60 (range, 27-80)   Retrospective: 53.9 Prospective: 48.9    A cutoff value of 3 ng/mL is optimal. Preoperative CEA above this level is associated with inferior overall and disease-free survival.

CEA, carcinoembryonic antigen; IQR, interquartile range; preop, preoperative; postop, postoperative; CRC, colorectal cancer.

Age: meanstandard deviation, mean ± standard deviation, or median (range), or median (IQR).

###### 

CEA and follow-up after CRC resection: selected studies

  Author                                     Year                            Origin        Study type                                Study summary                                                                                                      Endpoint                                         No. of patients   Age (yr), median (range)                                                    Sex ratio (%male)
  ------------------------------------------ ------------------------------- ------------- ----------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------ ----------------- --------------------------------------------------------------------------- ----------------------------------------------------
  Treasure \[[@b12-ac-2019-11-13]\]          1984 (published in full 2014)   UK            RCT                                       티evated CEA prompted randomization to either continued monitoring (conventional arm) or laparotomy (aggressive)   Survival                                         216               Conventional: 62 (35-75); aggressive: 64 (33-75)                            Conventional: 63; aggressive: 56
  Makela \[[@b72-ac-2019-11-13]\]            1995                            Finland       RCT                                       Intensive vs. conventional follow-up                                                                               Recurrence                                       106               Conventional: 69 (33-85); intensive: 63 (33-81)                             Conventional: 50; intensive: 48
  Ohlsson \[[@b20-ac-2019-11-13]\]           1995                            Sweden        RCT                                       No follow-up vs. intensive follow-up                                                                               Recurrence                                       107               \-                                                                          47.7
  Pietra \[[@b21-ac-2019-11-13]\]            1998                            Italy         RCT                                       Conventional or intense follow-up                                                                                  Recurrence                                       207               \-                                                                          \-
  Primrose \[[@b15-ac-2019-11-13]\]          2014                            UK            RCT                                       Intensive vs. minimal follow-up 3 different intensive groups                                                       Detection and curative treatment of recurrence   1,202             CT: 69 (62-76); CEA: 69 (6375); CT & CEA: 70 (64-76); minimal: 70 (63-75)   CT: 61.2; CEA: 61.3; CT & CEA: 61.3; minimal: 61.3
  Verberne \[[@b16-ac-2019-11-13]\]          2015                            Netherlands   RCT (stepped wedge)                       Standard vs. intensive follow-up                                                                                   CRC recurrence                                   3,223             70 (26-95)                                                                  56
  Wille-Jørgensen \[[@b13-ac-2019-11-13]\]   On-going trial                  Europe        Multicenter randomized controlled trial   Intensive vs. nonintensive follow-up                                                                               CRC recurrence and mortality                     \-                \-                                                                          \-
  Lepage \[[@b14-ac-2019-11-13]\]            On-going trial                  France        Multicenter randomized controlled trial   Standard vs. intensive follow-up                                                                                   5-year overall survival                          \-                \-                                                                          \-

RCT, randomized control trial; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CT, computed tomography.

###### 

CEA and follow-up after CRC: outcome measures in selected studies

  Trial                                                                                                                                                                                                                                                                                                                                               Type of regimen                                                                                                                                                                     Time to first recurrence (mo)                                                                                                                                                                                                                 Proportion of recurrences                                                                       Overall 5-year survival                                                                                                                     Outcome summary
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treasure (CEASL) \[[@b12-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                           All patients had clinical review 3/12 for 2 years and 6/12 for the next 3 years. CEA was measured monthly for the first 3 years and 3/12 for the next 2 years.                      Median time from primary surgery to CEA increases and randomization was 403 days (range, 103--1,754)                                                                                                                                          Conventional: 82%; aggressive: 77%                                                              Not reported. End of trial figures below                                                                                                    Second look laparotomy in the event of CEA elevation did not improve survival.
  Patients were randomized if the CEA became elevated (≥10 ng/mL).                                                                                                                                                                                                                                                                                    Conventional: 82% died                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  216 Patients were randomized.                                                                                                                                                                                                                                                                                                                       Aggressive: 84% died                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Conventional: Continued clinical monitoring with clinicians blinded to increased CEA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Aggressive: Clinician screen for widespread metastatic disease examinations and CXR. If not found, patient had a laparotomy to look for recurrence.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Makela \[[@b72-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                                     Clinic review for all 3/12 for 2 years, the 6/12 for 3 years with history, examination, complete blood cell counts, faecal occult bloods, CEA and CXR.                              Conventional: 15 ± 10; intensive: 10 ± 5                                                                                                                                                                                                      Conventional: 39%; intensive: 42%                                                               Conventional: 54%; intensive: 59%                                                                                                           Intensive follow-up leads to earlier detection of recurrence.
  USS liver every 6/12 and CT every year.                                                                                                                                                                                                                                                                                                             Most common sign indicating recurrence was CEA elevation in both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  In addition: Conventional: rigid sigmoidoscopy at each visit for those who had undergone surgery for rectal and sigmoid cancers, and a barium enema was done for all patients at 12 months and once a year thereafter; Intensive: colonoscopy 3 months after the surgery to ensure a clean colon and once a year thereafter on allpatients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Ohlsson \[[@b20-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                                    None/Control: No FU                                                                                                                                                                 \-                                                                                                                                                                                                                                            Control: 33%; intensive: 32%                                                                    Control: 67%; intensive: 75%                                                                                                                Intensive follow-up did not improve survival.
  Intensive: clinical exam, rigid sig, colonoscopy, CT pelvis (in patients with APR), pulmonary X-ray, liver function tests, CEA and faecal hemoglobin at 3-, 6-, 9-, 12-, 15-, 18-, 21-, 24-, 30-, 36-, 42-, 48-, and 60-month intervals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Pietra \[[@b21-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                                     Conventional: clinical exam + CEA and USS at 6/12 intervals for 1 year then annually thereafter.                                                                                    Conventional: 20.2 ± 6.1; iIntensive: 10.3 ± 2.7                                                                                                                                                                                              Conventional:19.4%; intensive: 25.2%                                                            Conventional: 58.3%; intensive: 73.1%                                                                                                       Intense follow-up leads to earlier detection of recurrent disease and improved survival.
  All patients received yearly CXR, colonoscopy and CT.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Intensive: As above, but with intervals 3/12 for 2 years then 6/12 for 3 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Primrose (FACS) \[[@b15-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                            Control: CT at 12--18 months or if symptomatic                                                                                                                                      \-                                                                                                                                                                                                                                            Cancer recurrence in 16.6% of patients, 5.9% of these surgically treated with curative intent                                                                                                                                               Intensive follow-up (any group) detected recurrence earlier and increased rate of curative surgical treatment. No advantage when using CT and CEA in combination. Could not demonstrate survival advantage.
  Intensive: CT: Scan of the chest, abdomen, and pelvis every 6 months for 2 years, then annually for 3. CEA: CEA every 3 months for 2 years, then every 6 months for 3 years, with a single CT scan at 12 to 18 months if requested at study entry by hospital clinician. CT and CEA: Both of the regimes combined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  All had colonoscopy at 2 and 5 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Rosati (GILDA) \[[@b18-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                             Control: Clinical review and CEA every 3 months for 2 years, then every 6 months for 3 years. Colonoscopy at 1 year. Liver USS at 4 months and 16 months.                           Intensive surveillance had earlier detection of 5.9 months (95% CI, 2.71--9.11)                                                                                                                                                               Overall recurrence rate: 20.4%; control: 18.7%; intensive: 22%                                  Control: 52.7%; intensive: 47.8%                                                                                                            Intensive surveillance detected recurrences earlier, but there was no difference in overall survival. Quality of life was not affected by surveillance strategy.
  Intensive: Clinical review and CEA as per control group. CBC and CA 19-9 included with CEA. Colonoscopy and CXR every 12 months. Liver USS every 4 months for 16 months, then yearly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Verberne (CEAWatch) \[[@b23-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                        Control: 5-year follow-up. Clinic every 6/12 for 3 years, then annually thereafter. Liver USS and CXR at each visit. CEA every 3 to 6 months for 3 years and annually thereafter.   Specific time interval not given; however, the authors stated that the time to diagnosis of recurrent disease decreased with the intensive follow-up protocol as compared to the control protocol (HR, 1.45; 95% CI, 1.08--1.95; P = 0.013)   Overall recurrence rate: 7.5%; control: 3.6%; intensive: 4.4%                                   No difference in OS or DFS between 2 arms. Survival significantly worse when detected by patients self-report rather than CEA or imaging.   An intensified protocol with CEA monitoring and assessment of CEA rise rather than absolute value detected recurrences earlier than the standard protocol. This does not affect overall or disease-free survival.
  Intensive: bimonthly CEA and yearly imaging for 3 years. CEA every 3/12 for next 2 years. Annual clinic review with imaging of chest and abdomen for 3 years. If 20% increase in CEA, another blood sample was drawn 4 weeks later. If a consecutive rise, CT scan of chest and abdomen was advised. Normal value was considered to be ≤2.5 ng/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wille-Jørgensen (COLOFOL) \[[@b13-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                  Nonintensive: CT scan of liver and lungs (or CT of liver + plain X-ray of lungs) + CEA after 12 and 36 months.                                                                      \-                                                                                                                                                                                                                                            \-                                                                                              \-                                                                                                                                          Recruitment ended 2015. Results awaited.
  Intensive: CT scan of liver and lungs (or CT of liver + plain X-ray of lungs) + CEA after 6, 12, 18, 24, and 36 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Lepage (PRODIGE 13) \[[@b14-ac-2019-11-13]\]                                                                                                                                                                                                                                                                                                        Standard: Abdo USS every 3/12 for 3 years, 6/12 for 2 years, then annually. CXR ever 6/12 for 3 years, then annually.                                                               \-                                                                                                                                                                                                                                            \-                                                                                              \-                                                                                                                                          Recruitment ended. Results awaited
  Intensive: A CT thorax/abdominal/pelvis alternating with abdominal USS every 3/12 for 3 years, then every 6/12 for 2 years. CEA every 3/12 for 3 years, then 6/12 2 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

FACS, Follow-up After Colorectal Surgery; GILDA, Gruppo Italiano di Lavoro per la Diagnosi Anticipata; CEAWatch, Carcino-Embryonic Antigen Watch; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CT, computed tomography; FU, follow-up; CXR, chest X-Ray; USS, UltraSound Scan; CBC, complete blood count; CI, confidence interval; HR, hazard ratio; OS, overall survival; DFS, disease-free survival.

###### 

CEA and screening/diagnosis: selected studies

  Author                             Year       Origin       Study type                                                                                                                                                            Asymptomatic vs. symptomatic   Endpoint                                                               No. of patients   Age (yr), median   Sex ratio (%male)   Outcome summary
  ---------------------------------- ---------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ---------------------------------------------------------------------- ----------------- ------------------ ------------------- ------------------------------------------------------------------------------------------------------
  Lee \[[@b32-ac-2019-11-13]\]       2011       Korea        Case control                                                                                                                                                          Asymptomatic                   Detection of colorectal cancer                                         546               \(A\) 56           A\) 77              4.6% of high CEA group had CRC compared to 1.3% of normal CEA group.
  \(A\) CEA ≥5 ng/mL                 \(B\) 54   B\) 73.4     CEA more likely to be elevated in advanced colorectal cancer.                                                                                                                                                                                                                                                                        
  \(B\) CEA ≤5 ng/mL                                                                                                                                                                                                                                                                                                                                                                              
  Nielsen \[[@b33-ac-2019-11-13]\]   2011       Denmark      Case control                                                                                                                                                          Symptomatic                    Detection of colorectal cancer                                         4,509             61                 45.9                CEA more likely to be elevated in advanced colorectal cancer. Median of 8.1 ng/mL in stage 4 disease
  Wild \[[@b35-ac-2019-11-13]\]      2010       Germany      Case control                                                                                                                                                          Mixed                          Comparison of serum-biomarker panel with Faecal occult blood testing   1,027             \(A\) 67           \(A\) 52.2          CEA more likely to be elevated in advanced colorectal cancer. 88.2% sensitivity in stage 4 disease.
  \(A\) CRC 301                      \(B\) 62   \(B\) 39.1                                                                                                                                                                                                                                                                                                                                        
  \(B\) GI disease control 104       \(C\) 66   \(C\) 58.7                                                                                                                                                                                                                                                                                                                                        
  \(C\) Adenoma 143                  \(D\) 62   \(D\) 46.1   CEA, seprase, CYFRA 21-1, ferritin and anti-p53 biomarker combination was comparable with faecal immunochemical testing with 82.4% versus 81.8% at 95% specificity,                                                                                                                                                                  
  \(D\) Other disease 141            \(E\) 64   \(E\) 42.6                                                                                                                                                                                                                                                                                                                                        
  \(E\) Other malignancy 176                                                                                                                                                                                                                                                                                                                                                                      
  Wen \[[@b34-ac-2019-11-13]\]       2015       Taiwan       Case control                                                                                                                                                          Mixed                          Detection of cancer using panel of 8 markers                           41,516                                                   CEA sensitivity 53.8%. Increases, when used in combination as panel of 8 biomarkers, to 76.9%

CEA, carcinoembryonic antigen; CRC, colorectal cancer; GI, gastrointestinal.

###### 

Conditions associated with elevated carcinoembryonic antigen (CEA) level

  Nonmalignant                                                                             Malignant
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------
  Smoking                                                                                  Tumors associated with high CEA expression
  Infections                                                                                Colorectal^[a](#tfn2-ac-2019-11-13){ref-type="table-fn"}^
  Peptic ulcer disease                                                                      Ovarian^[a](#tfn2-ac-2019-11-13){ref-type="table-fn"}^
  Inflammatory bowel disease                                                                Cervical^[a](#tfn2-ac-2019-11-13){ref-type="table-fn"}^
  Pancreatitis                                                                              Lung
  Hypothyroidism                                                                            Oesophageal
  Liver cirrhosis, hepatitis                                                                Gastric
  Benign breast conditions                                                                  Small intestinal
  Other benign tumors usually in organs where the cancers are associate with raised CEAd    Hepatobiliary
   Pancreatic                                                                              
   Breast                                                                                  
   Medullary                                                                               
  Other CEA-expressing tumors                                                              
   Choriocarcinoma                                                                         
   Osteosarcoma                                                                            
   Retinoblastoma                                                                          
   Hepatoma                                                                                
   Melanoma                                                                                
   Lymphoma                                                                                
   Urinary bladder, prostate and renal cell carcinoma                                      

CEA, carcinoembryonic antigen.

CEA monitoring used clinically.
